口服抗凝药与阿司匹林对结直肠癌筛查中粪便免疫化学检测性能的影响
在挪威一项正在进行的结直肠癌筛查试验中开展横断面研究,纳入粪便免疫化学检测阳性(>15 μg血红蛋白/g粪便)且接受结肠镜检查的50-74岁参与者,比较规律使用阿司匹林、华法林或直接口服抗凝药者与匹配非使用者的阳性预测值。阿司匹林和直接口服抗凝药使用者的结直肠癌及进展期腺瘤阳性预测值均低于匹配非使用者,华法林使用者与非使用者无显著差异。
要点
- 阿司匹林使用者结直肠癌阳性预测值为3.8%,匹配非使用者为6.4%(P = .006)。
- 直接口服抗凝药使用者结直肠癌阳性预测值为0.9%,匹配非使用者为6.8%(P = .001)。
- 华法林使用者与匹配非使用者的结直肠癌及进展期腺瘤阳性预测值无显著差异。
核心结论
- 在挪威大型筛查队列中,规律使用阿司匹林、尤其是直接口服抗凝药,与粪便免疫化学检测检出结直肠癌和进展期腺瘤的阳性预测值降低相关。
研究设计与样本
- 在挪威一项正在进行的结直肠癌筛查试验中开展的横断面研究,纳入50-74岁粪便免疫化学检测阳性(>15 μg血红蛋白/g粪便)且接受结肠镜检查(参考标准)的参与者。
- 规律使用阿司匹林、华法林或直接口服抗凝药者定义为使用者,非使用者按年龄、性别、筛查中心和筛查轮次匹配。
- 共纳入4908名符合条件的参与者,其中1008名使用阿司匹林、147名使用华法林、212名使用直接口服抗凝药、3541名为非使用者。
- 主要结局为结直肠癌和进展期腺瘤的阳性预测值。
主要发现
- 共发现234例结直肠癌和1305例进展期腺瘤。
- 结直肠癌阳性预测值:阿司匹林使用者3.8% vs 匹配非使用者6.4%(P = .006)。
- 进展期腺瘤阳性预测值:阿司匹林使用者27.2% vs 匹配非使用者32.6%(P = .011)。
- 结直肠癌阳性预测值:直接口服抗凝药使用者0.9% vs 匹配非使用者6.8%(P = .001)。
- 进展期腺瘤阳性预测值:直接口服抗凝药使用者20.5% vs 匹配非使用者32.4%(P = .002);华法林使用者与匹配非使用者的结直肠癌及进展期腺瘤阳性预测值无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The fecal immunochemical test (FIT) is the tool most frequently used for colorectal cancer (CRC) screening worldwide. It is unclear how the use of aspirin and oral anticoagulants in the screening population affects the diagnostic performance of FIT. METHODS: We performed a cross-sectional study in an ongoing CRC screening trial in Norway. Participants aged 50-74 years with a positive result from an FIT (>15 μg hemoglobin/g feces) and subsequent colonoscopy (reference standard) were included. Those who used regular aspirin, warfarin, or direct-acting oral anticoagulants (DOACs) were defined as users. Non-users were matched according to age, sex, screening center, and screening round. The primary outcomes were the positive predictive value (PPV) for CRC and advanced adenoma. RESULTS: Among 4908 eligible participants, 1008 used aspirin, 147 used warfarin, 212 used DOACs, and 3541 were non-users. CRCs were found in 234 individuals and advanced adenomas in 1305 individuals. The PPV for CRC was 3.8% for aspirin users vs 6.4% for matched non-users (P = .006), The PPV for advanced adenoma in aspirin users was 27.2% vs 32.6% for matched non-users (P = .011). For DOAC, the PPV for CRC was 0.9% in users vs 6.8% in matched non-users (P = .001). The PPV for advanced adenoma in DOAC users was 20.5% vs 32.4% in matched non-users (P = .002). There was no significant difference in PPV for CRC or advanced adenoma in warfarin users compared to non-users. CONCLUSIONS: In a large screening cohort in Norway, regular use of aspirin and particularly DOACs, were associated with lower PPV of FIT for detection of CRCs and advanced adenomas. ClinicalTrials.gov ID NCT01538550.
引用
- Randel KR, Botteri E, Romstad KMK, et al. Effects of Oral Anticoagulants and Aspirin on Performance of Fecal Immunochemical Tests in Colorectal Cancer Screening. Gastroenterology. 2019. PMID: 30689972. doi:10.1053/j.gastro.2019.01.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。